key: cord-0957873-2s3ps3vf
authors: Ganesh, Ravindra; Philpot, Lindsey M; Bierle, Dennis M; Razonable, Raymund R
title: Reply to Puing et al
date: 2021-08-11
journal: J Infect Dis
DOI: 10.1093/infdis/jiab407
sha: e8b642a76f1bab4993bc3167f4c02b4ef9c702b5
doc_id: 957873
cord_uid: 2s3ps3vf

nan

A c c e p t e d M a n u s c r i p t Dear Editor, We appreciate Puing et al in reporting their single-center retrospective study on the outcomes of anti-spike monoclonal antibodies in patients with cancer. [1] Their report complements our study on the comparative efficacy of bamlanivimab and casirivimabimdevimab in a large population of high-risk outpatients with mild to moderate COVID-19.

[2] Puing et al rightfully stated that data on the efficacy and safety of anti-spike monoclonal antibodies in the real-world setting are needed, particularly among the immunocompromised populations since they were not well represented in the clinical trials. [1, 3] Previous data have suggested that patients with hematologic malignancies are more prone to develop severe COVID-19 with hospitalization rates over 50% and mortality rates of 15-34%. [4, 5] In this report by Puing et al, the 30-day hospitalization rate of 12% among 42 patients with cancer is reassuringly lower than historical cohorts. However, the hospitalization rate is numerically higher than the 1-3% reported in randomized controlled trials of bamlanivimab and casirivimab-imdevimab. [6, 7] While comparing hospitalization rates among different studies is subject to differences in populations and many other variables, it is important to point out that the report by Puing et al is consistent with our observations. In our report, having an immunocompromised status is one of the major risk factors for hospitalization, despite receiving anti-spike monoclonal antibody infusion. [2] Among our high-risk cohort of 3596 patients, 535 had immunocompromised status as a risk factor. In this immunocompromised cohort, the 28-day hospitalization rate was 8.41% after bamlanivimab or casirivimab-imdevimab infusion. [2] In a separate subgroup analysis, the 28day hospitalization rate was 12.3% among 73 solid organ transplant patients who received bamlanivimab or casirivimab-imdevimab infusion for mild to moderate COVID-19. 

SARS-CoV-2 Specific Monoclonal Antibody for the Treatment of Mild-to-Moderate COVID-19 in Cancer Patients: A Single-center Experience

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19

A c c e p t e d M a n u s c r i p t